In December 2019, a novel member of the *Coronaviridae* family, severe acute respiratory syndrome (SARS)-coronavirus 2 (SARS-CoV-2), has spread rapidly throughout the world, probably from Wuhan, Hubei province, China, resulting in an infectious respiratory infection: coronavirus disease-19 (COVID-19).[@bib1], [@bib2], [@bib3] As of May 1, 2020, more than 3.2 million persons are confirmed to have contracted SARS-CoV-2, and nearly 250,000 have died from this global pandemic.[@bib4] This global public health emergency requires a rapid and effective response to mitigate COVID-19--related morbidity and mortality.[@bib2] Elucidating the mechanism of SARS-CoV-2 infection is necessary for the rational design of therapeutics, the use of novel or repurposed therapeutics, development of an effective vaccine, and understanding the clinical course of COVID-19.

Infections by the SARS coronaviruses---SARS-CoV and SARS-CoV-2---are dependent on host proteins angiotensin-converting enzyme 2 (ACE2) receptor, which has been the subject of multiple investigations in the literature.[@bib5] ^,^ [@bib6] However, viral entry requires not only binding to the ACE2 receptor but also priming of the virus's spike (S) protein by the transmembrane protease serine 2 (TMPRSS2) by cleavage of the S proteins at the S1/S2 and S2 sites. This cleavage step is necessary for the virus-host cell membrane fusion and cell entry.[@bib6] ^,^ [@bib7] One striking observation made across most countries is the increased severity of disease among older men with SARS-CoV-2 infection,[@bib8] although there might also be differences in infectivity. Although early data of 140 patients with SARS-CoV-2 from Wuhan, China, demonstrated a nearly equal male to female ratio for infection,[@bib9] subsequent studies of hospitalized and deceased patients have identified an increased male prevalence from approximately 55% to 85% in China,[@bib1] ^,^ [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] to 82% in Italy,[@bib17] and approximately 63% in New York City of hospitalized patients.[@bib18] It is interesting that this skewed sex difference in disease severity was also reported in studies of respiratory infections caused by related coronaviruses, SARS-CoV and Middle East respiratory syndrome (MERS)-CoV, suggesting a potentially shared underlying mechanism responsible for the high disease severity among infected men.[@bib19], [@bib20], [@bib21], [@bib22] Host susceptibility to severe COVID-19 disease is also associated with older age, hypertension, heart failure, chronic kidney disease, diabetes, obesity, and the use of ACE inhibitors.[@bib22], [@bib23], [@bib24] Although gender can be associated with these additional comorbidities, male sex remains an independent variable associated with severe COVID-19 infection in multiple studies.[@bib22] ^,^ [@bib23]. It is possible that expression differences in ACE2 and TMPRSS2 explain the increased severity of disease among men. ACE2 is located at Xp22.2, within the nonpseudoautosomal portion of the X chromosome (15,561,033-15,602,069, GRCh38). It displays incomplete X-chromosome inactivation and shows a male-biased expression pattern in several tissues.[@bib25] TMPRSS2 is located at 21q22.3, within chromosome 21 (41,464,305-41,508,158, GRCh38), and its expression is modulated by androgen signaling via multiple androgen receptor elements upstream of the gene's transcriptional start site.[@bib26] ^,^ [@bib27] In this study, we evaluate the expression levels of both ACE2 and TMPRSS2 in many host tissues, including lung. Given the increased severity of disease among older men with SARS-CoV-2 infection, we also address the potential roles of ACE2 and TMPRSS2 in their contribution to the sex differences in severity of disease.

Methods {#sec1}
=======

ACE2 and TMPRSS2 Gene Expression Analyses {#sec1.1}
-----------------------------------------

ACE2 and TMPRSS2 expression data were obtained directly from the genotype-tissue expression (GTEx) project (<https://gtexportal.org>) or from the Human Protein Atlas GTEx data (RNAseq based on RSEMv1.2.22 (v7). Expression from all tissue samples available were plotted using the box plots available from the GTExPortal website with plots shown as median and 25th and 75th percentiles and dots displayed as outliers if they are above or below 1.5 times the interquartile range. Comparison of ACE2 and TMPRSS2 expression was performed using GTEx tool multiGeneQueryPage.

Statistical Analyses {#sec1.2}
--------------------

From the Human Protein Atlas GTEx data (RNAseq based on RSEMv1.2.22 (v7), box plots were created using SPSS Software (SPSS Statistics, IBM, Chicago, Illinois) and extreme outliers in each type of sample were identified (data not shown). If extreme outliers were present in the sample population, the significance of the difference was calculated using the Mood's median test. For all other samples without extreme outliers, Kruskal--Wallis was used to calculate the significance.

TMPRSS2 Allele Frequencies {#sec1.3}
--------------------------

Allele frequency of 2 missense variants rs75603675 and rs12329760 in TMPRSS2 gene were calculated using the Geography of Genetic Variants Browser.[@bib28]

Results {#sec2}
=======

Expression of ACE2 and TMPRSS2 in Multiple Tissues {#sec2.1}
--------------------------------------------------

Given the necessity of ACE2 and TMPRSS2 genes for SARS CoV-2 infection, we evaluated their expression in human tissues using data from the GTEx project (<https://gtexportal.org>). Expression of ACE2 and TMPRSS2 was detectable in multiple tissues. As the common symptoms of COVID-19 involve cough, sore throat, gastrointestinal issues, anosmia, and dysgeusia,[@bib14] ^,^ [@bib29] we analyzed the levels of ACE2 and TMPRSS2 in tissues associated with these sequelae. Both ACE2 and TMPRSS2 were expressed in the lung, with expression levels of TMPRSS2 higher than ACE2 ([Figure 1](#fig1){ref-type="fig"} ). Tissues associated with the gastrointestinal system with elevated ACE2 expression include small intestine (terminal ileum), colon (transverse), esophagus (mucosa), minor salivary gland and pancreas, esophagus, liver, colon (sigmoid) and stomach ([Figure 1](#fig1){ref-type="fig"}A). TMPRSS2 expression was also detected in gastrointestinal tissues including stomach, colon (transverse), pancreas, small intestine (terminal ileum), minor salivary gland, esophagus (mucosa), liver, and colon (sigmoid) ([Figure 1](#fig1){ref-type="fig"}B). Some patients with COVID-19 experience anosmia and dysgeusia, findings that may be a result of olfactory nerve abnormalities.[@bib29] Although GTEx does not have expression data specifically from olfactory tissues, the overall expression levels of both ACE2 and TMPRSS2 appear low in other nervous system tissues. The highest expression of ACE2 was observed in the testes, and the prostate displayed the highest expression of TMPRSS2 ([Figure 1](#fig1){ref-type="fig"}). Although the overall expression of ACE2 and TMPRSS2 varied in each tissue, multiple tissues expressed both ACE2 and TMPRSS2 ([Figure 1](#fig1){ref-type="fig"}C). However, some tissues---such as adipose, heart, artery, and ovary---had high ACE2 and low TMPRSS2 expression, whereas the prostate, stomach, bladder, skin, liver, and pituitary had high TMPRSS2 and low ACE2 expression ([Figure 1](#fig1){ref-type="fig"}C). Although the pathophysiology of SARS-CoV-2 is not completely understood, and these data alone cannot establish causality between infection and ACE2 or TMPRSS2 expression, they do suggest that additional tissues other than the lung---including, but not limited to, kidney, testes, and skin---may also be infected by SARS-CoV-2. This observation may explain the pleiotropic effects of SARS-CoV-2 infection but should be confirmed *in vitro* and *in vivo.* [@bib30], [@bib31], [@bib32] Figure 1ACE2 and TMPRSS2 gene expression data. The data were obtained directly from the Genotype-Tissue Expression (GTEx) Project (<https://gtexportal.org>). Samples were sorted based on the median expression on a log scale using transcripts per million (TPM) unit. ACE2 **(A)** and TMPRSS2 **(B)** expression from all tissue samples available were plotted using the box plots available from the GTExPortal website with plots shown as median and 25th and 75th percentiles and dots displayed as outliers if they are above or below 1.5 times the interquartile range. Red boxes show the testes and prostate expression of ACE2 and TMPRSS2, respectively. Tissues associated with common COVID-19 symptoms are marked with an asterisk∗. In **(C)**, a comparison of ACE2 and TMPRSS2 expression using GTEX tool multiGeneQueryPage.

Expression of ACE2 and TMPRSS2 is Similar in Men and Women {#sec2.2}
----------------------------------------------------------

Although the frequency of men and women testing positive for SARS-CoV-2 may be similar, men are more likely to die (60% men vs 40% women) following the infection compared with women, an observation that does not appear to be geographically specific ([Table 1](#tbl1){ref-type="table"} ). To evaluate whether ACE2 or TMPRSS2 contribute to the sex disparity in severity of disease, we analyzed their sex differential gene expression using the GTEx data that were available directly through the GTEx portal and also through the Human Protein Atlas (<https://proteinatlas.org>) ([Figure 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"} ). Focusing on the tissues with the highest expression of ACE2 and TMPRSS2, only the subcutaneous adipose tissue showed a significant difference between sex, with men displaying lower median ACE2 expression compared with women ([Table 2](#tbl2){ref-type="table"}) (men 1.3 transcripts per million \[TPM\] vs women 2.2 TPM, *P* value \<0.0001). In some tissues, a higher numerical median expression of ACE2 (lung: men 0.7 vs women 0.6; thyroid gland: men 4.4 vs women 3.4; heart atrial appendage: men 3.6 vs 3.4 women; and visceral adipose: men 5.5 vs women 5.4 TPM) and TMPRSS2 (colon transverse: men 104.1 vs women 90.8; pancreas: men 52.7 vs women 51.0; salivary gland: men 46.3 vs women 42.5; and esophagus: men 32.7 vs women 28.8 TPM) was observed ([Table 2](#tbl2){ref-type="table"}); however, these findings were not considered significant. No significant differences in ACE2 or TMPRSS2 expression were observed in lung tissue ([Table 2](#tbl2){ref-type="table"}).Table 1Sex Disaggregated Information From 32 Countries With 982, 274 Total Cases As Of May 2, 2020CountryTotal casesTotal casesTotal casesCasesCasesTotal deathsTotal deathsTotal deathsDeathsDeathsDeathsDeathsDeaths confirmed+(M)(F)(% M)(% F)(M)(F)(% M)(% F)confirmed + (% M)confirmed + (% F)(M:F ratio)The Netherlands38,36514,57923,7863862456626031963574317.98.32.2Finland4740227524654852145757052483.32.81.2Denmark885137175134425843424718757436.73.61.8Greece23241278104655451321003276247.83.02.6Italy176,71686,59190,125495123,16414,5938571633716.99.51.8Republic of Ireland19,666826011,406425890347942453475.83.71.6Spain204,85690,137114,719445615,85391956658584210.25.81.8Switzerland29,37613,51315,8634654140881759158426.03.71.6Belgium47,68217,64230,0403763528626962590514915.38.61.8Germany156,33775,04281,295485259083368254057434.53.11.4Portugal24,322997214,350415994846548349514.73.41.4Austria15,31475047810495155030824256444.13.11.3Sweden19,621882910,7924555235513421013574315.29.41.6Northern Ireland272411171607415920611591564410.35.61.8Norway76053726387949511951078855452.92.31.3Romania11,31350916222455561939622364367.83.62.2Ukraine941041405270445623913110855453.22.01.6Luxembourg374119081833514989503956442.62.11.2Europe**782,963355,322427,641455563,00037,08725,913594110.46.11.7**Dominican Republic62933398289554462822206278226.52.13.0Peru28,69917,79310,906623878255522771293.12.11.5Mexico15,5299007652258421434975459683210.87.01.5Colombia55972910268752482531579662385.43.61.5Ecuador15,72886507078554587159227968326.83.91.7Canada26,63811,72114,9174456106753453450504.63.61.3Argentina38921946194650501921256765356.43.51.9Americas**102,37655,42646,950544648813158172365355.73.71.6**China55,92428,52127,40351492114135376164364.72.81.7South Korea10,75243016451406024412711752483.01.81.6Australia671333573357505084513361391.51.01.6Philippines795542963659544653035018066348.14.91.7Indonesia951156113900594177352624768329.46.31.5Thailand293816161322554552401277232.50.92.7Asia**93,79347,70246,091514937972447135064365.12.91.8**South Africa**314214141728455543241956441.71.11.6**Total**982,274459,863522,411475371,72142,71629,00560409.35.61.7**[^1][^2]Figure 2Sex differences in TMPRSS2 and ACE2 expression data. The data were obtained directly from the Genotype-Tissue Expression (GTEx) Project (<https://gtexportal.org>). Female subjects (pink) and male subjects (blue) were arranged based on sorting using the median expression on a log scale using transcripts per million (TPM) unit. TMPRSS2 **(A)** or ACE2 **(B)** expression from all tissues available were plotted using the box plots available from the GTExPortal website with plots shown as median and 25th and 75th percentiles with dots displayed as outliers if they are above or below 1.5 times the interquartile range.Table 2Median ACE2 and TMPRSS2 TPM Expression Values.TMPRSS2*Male median TPMFemale median TPM*P valueStomach109.4132.50.309Colon-transverse104.190.80.460Small intestine63.686.10.186Lung48.249.50.244Pancreas52.751.00.436Salivary gland46.342.50.228Esophagus32.728.80.649Kidney31.631.10.876Thyroid21.621.10.921Liver12.214.60.284ACE2Male median TPMFemale median TPM*P* valueSmall intestine38.050.70.385Adipose tissue subcutaneous1.32.2\<0.0001Adipose tissue visceral5.55.40.971Thyroid gland4.43.40.059Kidney4.78.80.104Heart atrial appendage3.63.40.563Heart left ventricle4.75.70.104Colon-sigmoid0.20.20.769Colon-transverse3.34.00.460Lung0.70.60.574Salivary gland1.51.60.636[^3][^4]

Discussion {#sec3}
==========

The rapid development of novel approaches or repurposing of existing therapies is critical in mitigating the coronavirus pandemic. Because of the centrality of ACE2 and TMPRSS2 as host-expressing genes necessary for SARS-CoV-2 infection and subsequent immune reactions[@bib34] ([Figure 3](#fig3){ref-type="fig"} ), it is reasonable to develop agents that target their proteins or inhibit their activity.[@bib35] Therapies that target ACE2 received some focus in the literature,[@bib36] and the use of decoy ACE2 receptors could have promise.[@bib37] However, directly antagonizing human ACE2 may be challenging owing to the essential regulatory role of ACE2 in heart function, as demonstrated by the severe cardiac defects observed in ACE2 knockout (KO) mice.[@bib38] Furthermore, there are potentially beneficial effects of ACE2 that occur because of the degradation of angiotensin I and angiotensin II by ACE2. By contrast, TMPRSS2 KO mice lack an observable phenotype and appear healthy, suggesting that TMPRSS2 is nonessential for mouse reproduction, development, and growth.[@bib39] Further, TMPRSS2 KO mice had reduced infection and virus spread within the airway and less severe immune response due to SARS-CoV and the related MERS-CoV viruses, demonstrating the critical role of TMPRSS2 in coronavirus infection.[@bib40] Figure 3Schematic of SARS-CoV-2 infection of host tissue and disease pathogenesis. SARS-CoV-2 infects host cells (primarily epithelial cells) that express the host receptor, ACE2 and TMPRSS2, resulting in phase I of infection. In phase II, viral proliferation occurs in infected cells and this results in a local immune response, release of cytokines and chemokines (black circles), attraction of macrophages (green cell) and T cells (orange cell) to infected cells, and activation of further adaptive immune responses. In most cases, there is a healthy immune response, and infected cells are eliminated and further viral infection can be blocked by neutralizing antibodies (green). In this phase III of infection, there is a reduction of virus spread, resolution of infection, suppression of inflammation with limited tissue injury, and eventual recovery. However, in some cases of phase III of infection, the viral infection may lead to increased production of proinflammatory cytokines, resulting in a cytokine storm, causing multiorgan damage and acute respiratory distress syndrome (ARDS).

Inhibition of TMPRSS2 activity using camostat mesylate in human lung cells *in vitro* has a demonstrated efficacy against SARS-CoV-2 infection.[@bib6] Therefore, this agent appears to be a logical therapeutic approach, as it is already used in Japan to treat pancreatitis.[@bib41] Given the strong preclinical support of repurposing camostat mesylate for SARS-CoV infection, clinical trials evaluating camostat mesylate alone or in combination with hydroxychloroquine have begun in Europe (<https://clinicaltrials.gov/ct2/show/NCT04321096> and <https://clinicaltrials.gov/ct2/show/NCT04338906>), and we are actively pursuing them in the United States. In addition, another TMPRSS2 inhibitor---nafamostat---may also have clinical utility against SARS-CoV-2 infection.[@bib42]

An alternative strategy is to inhibit the androgen receptor (AR). The TMPRSS2 expression is modulated by androgen signaling via multiple androgen receptor elements upstream of the gene's transcriptional start site.[@bib26] ^,^ [@bib27] As shown in [Figure 1](#fig1){ref-type="fig"}B, and by others, TMPRSS2 is highly expressed in prostate epithelium.[@bib26] Consistent with this, an aberrant fusion of TMPRSS2 with ERG or with other partner oncogenes (ETV1, ETV4, ETV5) is a common feature in prostate cancer.[@bib43] As it is well documented that TMPRSS2 is an androgen-responsive gene, a novel approach to SARS-CoV-2 infection may be to reduce the expression of TMPRSS2 by inhibition of AR signaling through the use of androgen deprivation therapy (ADT) or antiandrogens, which are standard treatments for prostate cancer.[@bib44] Although preclinical studies are necessary to evaluate this novel approach to SARS-CoV-2 infection, it has the benefit that the use and low toxicity profile of AR-directed therapies have been well established in prostate cancer studies.[@bib44] Targeting TMPRSS2 protease activity through protease inhibitors or indirectly through ADT requires an understanding of the functional polymorphisms present in the gene. Of the 13 common markers (minor allele frequency 0.5) within TMPRSS2, there are 2 missense variants (rs75603675; c.23G\>T p.Gly8Val and rs12329760; c.589G\>A p.Val197Met) whose frequencies vary by ancestry and geography ([Figure 4](#fig4){ref-type="fig"} ). Targeting TMPRSS2 protease activity through protease inhibitors or indirectly through ADT will require additional studies to determine the role of rs75603675 and rs12329760 on TMPRSS2 expression, protease activity, and in response to protease inhibition.Figure 4Allele frequency of 2 missense variants rs12329760 and rs75603675 in TMPRSS2 gene. The allele frequencies were calculated using the Geography of Genetic Variants Browser.[@bib28] Genomic positions in GRCh37.

Our observations are consistent with previous studies evaluating TMPRSS2 expression in lung tissue using GTEx data,[@bib45] although---owing to the limitation of the data---they do not consider age, menopausal status, or ancestry. Although a very slight increase in TMPRSS2 expression was observed in the bronchial epithelial cells of male patients compared with female patients, using GSE66499 microarray data,[@bib45] it is unclear whether this small increase in TMPRSS2 expression explains the increase in severity of disease in men. Our results are also consistent with previous studies supporting no significant differences in ACE2 expression in lung tissue in association with age (\>60 and \<60 years), race (white and Asian), and sex using RNAseq, microarray, and GTEx datasets.[@bib46] Combined, these findings suggest that differences in the expression levels of TMPRSS2 and ACE2 in the lung and other non--sex-specific tissues likely do not explain the gender disparities in severity of SARS CoV-2. However, the observation of high ACE2 expression in the testes is an intriguing observation, and a recent study hypothesized that the testes could serve as a reservoir for SARS-CoV-2.[@bib30] However, the expression of genes in the testes has been associated with "leaky expression," without evidence of a functional consequence of the expressed genes.[@bib47] Therefore, the expression of ACE2 in the testes warrants additional investigation, including demonstration of SARS-CoV-2 in semen. Additional studies are also needed to evaluate whether androgens (or even estrogens) contribute to sex-associated severity of disease independently of ACE2 or TMPRSS2 functions.

Conclusion {#sec4}
==========

SARS-CoV-2 has rapidly caused a global pandemic. Both ACE2 and TMPRSS2 are expressed in many host tissues, but the expression levels of ACE2 and TMPRSS2 are overall comparable between men and women in multiple tissues. This suggests that expression differences of TMPRSS2 and ACE2 in the lung and other non--sex-specific tissues may not explain the gender disparities in severity of SARS CoV-2. However, targeting the activity and expression levels of TMPRSS2 is a rational approach to treat COVID-19 and should be explored further.
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[^1]: The data were obtained from the Global Health 5050[@bib33] (<http://globalhealth5050.org/covid19>) tracker. Data from Iran, India, and Pakistan are not indicated in table. Regions were color-coded as follows: Europe (purple), Americas (green), Asia (orange), and Africa (blue).

[^2]: Confirmed + = confirmed positive

[^3]: The data were obtained from The Human Protein Atlas GTEx data (RNAseq based on RSEMv1.2.22 \[v7\]) and sorted from the highest expressing tissues from male and female patients (all age groups included). Box plots were created using SPSS Software (IBM, Chicago, Illinois), and extreme outliers in each type of sample were identified. If extreme outliers were present in the sample population, the significance of the difference was calculated using the Mood's median test. For all other samples without extreme outliers, Kruskal--Wallis was used to calculate the significance.

[^4]: TPM = transcripts per million.
